Form D · Biotechnology
MYOTHERIX, INC.
Emeryville, CA · CIK 0001647149
Offering snapshot reported Mar 1, 2017 · SEC filing
- Reported sold
- $7.93M Offering amount: $7.93M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 14, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2017 | Initial | $7,930,719 | No comparison | 15 | SEC filing |
| Sep 26, 2016 | Initial | $500,000 | No comparison | 9 | SEC filing |
| Jul 8, 2015 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-281503
Source: Form D, filed Mar 1, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark P De Souza | Director, Executive |
| Babar Ghias | Director |
| Michael Kelly | Director, Executive |
| John Kincaid | Director, Executive |
| Jak Knowles | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1900 Powell Street, 6th Floor
Emeryville, CA, 94608
Emeryville, CA, 94608